Skip to main content

Management of Neovascular Age-Related Macular Degeneration: Improving Patient Outcomes

A Series of CME-certified Live Webinars

Click here to complete your registration.

Wednesday, September 9, 2020
6:30 - 7:30 PM ET (5:30 - 6:30 PM CT / 3:30 - 4:30 PM PT)
Hosted by: Maryland Society of Eye Physicians and Surgeons

Friday, September 25, 2020
4:00 - 5:00 PM ET (3:00 - 4:00 PM CT / 1:00 - 2:00 PM PT)
Hosted by: New Jersey Academy of Ophthalmology

Thursday, October 8, 2020
4:00 - 5:00 PM ET (3:00 - 4:00 PM CT / 1:00 - 2:00 PM PT)
Hosted by: Rhode Island Society of Eye Physicians and Surgeons

Saturday, October 10, 2020
10:00 - 11:00 AM ET (9:00 - 10:00 AM CT / 7:00 - 8:00 AM PT)
Hosted by: Kentucky Academy of Eye Physicians and Surgeons

Wednesday, October 21, 2020
7:30 - 8:30 PM ET (6:30 - 7:30 PM CT / 4:30 - 5:30 PM PT)
Hosted by: Louisiana Academy of Eye Physicians and Surgeons

Thursday, October 22, 2020
7:00 - 8:00 PM ET (6:00 - 7:00 PM CT / 4:00 - 5:00 PM PT)
Hosted by: Florida Society of Ophthalmology

Welcome and Introduction
Understanding the Current and Emerging nAMD Treatment Landscape
Improving Adherence to Anti-VEGF Therapy
Case Presentation
Q&A Session and Concluding Remarks

Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss and blindness in older Americans. While there are multiple anti-VEGF agents for nAMD, real-world outcomes are significantly lower than those demonstrated in clinical trials. In order to help overcome this discrepancy, ophthalmologists should be kept up to date regarding the most recent approvals and related trial data, as well as being given strategies and tools to overcome patients’ lack of adherence to anti-VEGF therapies.

This CME activity, Management of Neovascular Age-Related Macular Degeneration: Improving Patient Outcomes, will help clinicians understand the latest nAMD advances and optimize patient outcomes.

Jennifer I. Lim, MD, FARVO
Marion H. Schenk Chair
Professor of Ophthalmology
Director of the Retina Service
University of Illinois at Chicago
Chicago, IL

Jennifer I. Lim, MD, FARVO holds the Marion H. Schenk Chair in Ophthalmology for Research in the Aging Eye as a Professor of Ophthalmology and Director of the Retina Service at the University of Illinois at Chicago. Her areas of expertise include surgical and medical retinal diseases. She received her medical doctorate with distinction from Northwestern University, where she received both the Dean’s AOA Student Research Award and the Julius Conn Memorial Award. She completed her ophthalmology training at University of Illinois at Chicago, receiving the Resident Research Award and the American College of Surgeons Resident Competition Chicago Chapter Keeshin Prize.

She completed medical and surgical retina fellowships at the Wilmer Eye Institute of Johns Hopkins Hospital, where she was a Heed Fellow and a Heed Knapp Fellow Awardee. After completing her training, she joined the faculty of Emory University as an Assistant Professor of Ophthalmology. She was recruited to Doheny Eye Institute of University of Southern California as an Associate Professor with tenure and then promoted to Professor of Ophthalmology. In 2007, she was recruited to University of Illinois at Chicago as the Director of the Retina Service.

Her research interests include clinical trials, translational research, and retinal vascular disease. She has been principal investigator for more than 60 clinical trials. She collaborates with basic scientists on angiogenesis and imaging research and has received funding from the National Eye Institute, Macula Society Research Fund, American Cancer Society, and numerous industry grants. Her current leadership positions include Deputy Associate Editor for JAMA Ophthalmology, EyeWiki Retina Section Editor, Treasurer of the Retina Society, Chair of the Nominating Committee of Macula Society, and Vice President of the Chicago Ophthalmology Society. She serves as an Associate Examiner of the American Board of Ophthalmology (ABO) and has served on the Maintenance of Certification Committee of the AAO.

Among numerous honors, she has received the AAO Lifetime Achievement Award (2018), ARVO Gold Fellow Award (2019), Silver Fellow Award (2014), and Mother McAuley Liberal Arts High School Hall of Honor (2019). She was the inaugural University of Illinois at Chicago Distinguished Sweeney Lecturer and was named to Chicago Super Docs, Best Doctors in America, Top Doctors, and the ASRS Retina Hall of Fame (charter inductee). She has authored or co-authored more than 300 articles and 30 book chapters and edited several books, including Age-Related Macular Degeneration, which is currently in its Third Edition.

Quan Dong Nguyen, MD, MSc
Professor of Ophthalmology
Byers Eye Institute
Spencer Center for Vision Research
Wu Tai Neurosciences Institute
Stanford University School of Medicine
Stanford, CA

Quan Dong Nguyen, MD, MSc was born in Saigon, Vietnam, and immigrated with his parents and three brothers to the United States in 1980. He is currently Professor of Ophthalmology at the Byers Eye Institute at Stanford University School of Medicine.

After completing his education at the Phillips Exeter Academy, Yale, University of Pennsylvania, and Harvard in 2001, Dr. Nguyen joined the faculty at the Wilmer Eye Institute at Johns Hopkins as Assistant Professor and then Associate Professor of Ophthalmology and Director of Medical Education. In 2013, he was appointed as the McGaw Endowed Chair in Ophthalmology, Professor and Chairman of the Department of Ophthalmology, and the Inaugural Director of the Stanley M. Truhlsen Eye Institute, as well as Assistant Dean for Translational Research at the University of Nebraska Medical Center.

Dr. Nguyen is the principal investigator for multiple clinical trials sponsored by the National Eye Institute and other organizations on macular edema (from diabetes and uveitis), neovascular age-related macular degeneration (AMD), and ocular inflammatory and uveitic diseases. Dr. Nguyen is known for his innovative work in early proof-of-concept, first-in-human clinical trials to evaluate potential pharmacotherapeutic agents for retinal vascular and uveitic diseases. He and his team were among the first scientists in the world to evaluate aflibercept for neovascular AMD and ranibizumab for diabetic macular edema (DME); the initial results of these studies served as the foundation for subsequent trials leading to the approval of these pharmacologic agents by the FDA and other regulatory authorities for the indicated diseases. Dr. Nguyen has chaired the US multi-center READ-2, READ-3, and iDEAL studies, evaluating the potential role of VEGF antagonists through different pathways for DME.

Dr. Nguyen led the SAVE and multi-centered SAVE-2 and STOP-UVEITIS studies to evaluate the role of new pharmacologic agents, including specific interleukin inhibition in uveitis and ocular inflammatory diseases. Throughout his career, Dr. Nguyen has shared his scientific work through numerous manuscripts published in the literature. He serves on the Editorial Board of several journals, including the Journal of Ophthalmic Infection and Inflammation and Ophthalmic Surgery, Laser, and Imaging – Retina, among others.

At the Byers Eye Institute at Stanford, Dr. Nguyen has an active practice for uveitis and ocular inflammatory diseases, as well as clinical and surgical retina procedures, while he continues his research in pharmacotherapy and ocular imaging. In addition, he teaches and trains students, residents, and fellows from the United States and around the world.

The intended audience for this initiative is ophthalmologists involved in the management of adults with nAMD.

This program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of this activity, participants should be able to:

  • Evaluate the latest clinical trial data for the agents currently approved, used off-label, and in development for nAMD 
  • Incorporate available approved and off-label treatments into precision-based nAMD management plans 
  • Indicate strategies to encourage adherence to anti-VEGF treatment in patients with nAMD
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. Trustees of Boston University makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will trustees of Boston University be liable to anyone for any decision made or action take in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

The faculty and steering committee reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Jennifer I. Lim, MD, FARVO: Grant/Research Support: Chengdu, Graybug, Genentech, Regeneron, Stealth; Speaker: Genentech; Consultant (Advisory Boards): Allergan, Genentech, Kodiak, Novartis, pSivida; DMC Member: Aura, Opthea, Santen

Quan Dong Nguyen, MD, MSc: Advisory Board: Aerie, Bayer, EyePoint, Genentech, Gilead, Regeneron, Santen; Grant/Research Support: Aerie, Genentech, Gilead, Regeneron, Santen

Manju Subramanian, MD (CME Course Director): Nothing to disclose

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Terry Ann Glauser, MD, MPH; Nicolle Rochino, PharmD; Joanne M. Faysal; Blair St. Amand; Elizabeth Drury; Natalie Sanfratello, MPH: Nothing to disclose

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of a
pproved uses.

To ensure your computer is compatible for the live event, please perform a system check by clicking on the link or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test with a score of 70% or better and the evaluation. The estimated time for completion of this activity is 1 hour. To receive a certific
ate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

Jointly provided by Boston University School of Medicine and Rockpointe

Supported by an independent educational grant from Novartis Pharmaceuticals Corporation